Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Next Previous
Trial Profile

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs AR 42 (Primary)
  • Indications Meningioma; Neurilemmoma
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 11 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
    • 11 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Aug 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top